JP2006519799A - Ｉｐ−１０が媒介した疾患の処置又は予防用の、チアゾリジンジオンを有する薬学的調製物 - Google Patents

Ｉｐ−１０が媒介した疾患の処置又は予防用の、チアゾリジンジオンを有する薬学的調製物 Download PDF

Info

Publication number
JP2006519799A
JP2006519799A JP2006504502A JP2006504502A JP2006519799A JP 2006519799 A JP2006519799 A JP 2006519799A JP 2006504502 A JP2006504502 A JP 2006504502A JP 2006504502 A JP2006504502 A JP 2006504502A JP 2006519799 A JP2006519799 A JP 2006519799A
Authority
JP
Japan
Prior art keywords
treatment
thiazolidinedione
preparation
transplantation
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006504502A
Other languages
English (en)
Japanese (ja)
Inventor
ガッリ・アンドレア
ロマグナニ・パオラ
セリオ・マリオ
スレンティ・カロゲロ
Original Assignee
ユニヴァーシタ’デグリ ステュディ ディ フィレンツェ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシタ’デグリ ステュディ ディ フィレンツェ filed Critical ユニヴァーシタ’デグリ ステュディ ディ フィレンツェ
Publication of JP2006519799A publication Critical patent/JP2006519799A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
JP2006504502A 2003-03-06 2004-03-02 Ｉｐ−１０が媒介した疾患の処置又は予防用の、チアゾリジンジオンを有する薬学的調製物 Pending JP2006519799A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000058A ITFI20030058A1 (it) 2003-03-06 2003-03-06 Formulazioni farmaceutiche contenenti tiazolidinedioni
PCT/EP2004/002069 WO2004078175A2 (fr) 2003-03-06 2004-03-02 Preparations pharmaceutiques contenant des thiazolidinediones presentant de nouvelles indications therapeutiques

Publications (1)

Publication Number Publication Date
JP2006519799A true JP2006519799A (ja) 2006-08-31

Family

ID=32948189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504502A Pending JP2006519799A (ja) 2003-03-06 2004-03-02 Ｉｐ−１０が媒介した疾患の処置又は予防用の、チアゾリジンジオンを有する薬学的調製物

Country Status (14)

Country Link
US (1) US20060287372A1 (fr)
EP (2) EP1601355B1 (fr)
JP (1) JP2006519799A (fr)
AT (1) ATE368859T1 (fr)
AU (1) AU2004216823B2 (fr)
CA (1) CA2518199A1 (fr)
CY (1) CY1108098T1 (fr)
DE (1) DE602004007895T2 (fr)
DK (1) DK1601355T3 (fr)
ES (1) ES2290678T3 (fr)
IT (1) ITFI20030058A1 (fr)
PL (1) PL1601355T3 (fr)
PT (1) PT1601355E (fr)
WO (1) WO2004078175A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
ITFI20040243A1 (it) * 2004-11-25 2005-02-25 Paola Romagnani Metodo diagnostico per la previsione di rigetto di organo trapiantato
GB0504206D0 (en) * 2005-03-01 2005-04-06 Glaxo Group Ltd Combination therapy
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
PL2001469T3 (pl) 2006-03-16 2012-10-31 Metabolic Solutions Dev Co Llc Analogi tiazolidynodionu
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200927731A (en) 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
EP2643320B1 (fr) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. Dérivés de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
EP2649069B1 (fr) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
EP2661435B1 (fr) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
US20190350907A1 (en) * 2017-01-16 2019-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040517A2 (fr) * 1999-11-30 2001-06-07 Oxo Chemie Ag Evaluation et prediction cliniques obtenues par analyse d"expression genique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0767790B1 (fr) * 1994-06-20 2001-12-12 Takeda Chemical Industries, Ltd. Composes d'imidazole condenses, leur production et utilisation
KR20000016074A (ko) * 1996-05-31 2000-03-25 가와무라 요시부미 자기면역질환 치료제
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
WO2000030628A2 (fr) * 1998-11-20 2000-06-02 Genentech, Inc. Methode d'inhibition de l'angiogenese
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
WO2001062238A2 (fr) * 2000-02-24 2001-08-30 San Diego State University Procede servant a traiter des maladies du foie associees a la fonction hepatique
US20020019344A1 (en) * 2000-02-26 2002-02-14 Pershadsingh Harrihar A. Methods of preventing allograft rejection
US20020018776A1 (en) * 2000-04-14 2002-02-14 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CXCR3 function
FR2823225B1 (fr) * 2001-04-04 2004-09-17 Pierre Desreumaux Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
US7244555B2 (en) * 2002-05-14 2007-07-17 Renovak Inc Systems and methods for identifying organ transplant risk

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040517A2 (fr) * 1999-11-30 2001-06-07 Oxo Chemie Ag Evaluation et prediction cliniques obtenues par analyse d"expression genique

Also Published As

Publication number Publication date
WO2004078175A2 (fr) 2004-09-16
DE602004007895T2 (de) 2008-04-17
EP1601355A2 (fr) 2005-12-07
ATE368859T1 (de) 2007-08-15
US20060287372A1 (en) 2006-12-21
EP1830191A2 (fr) 2007-09-05
DK1601355T3 (da) 2007-12-17
PL1601355T3 (pl) 2007-12-31
EP1830191A3 (fr) 2007-10-03
CY1108098T1 (el) 2014-02-12
DE602004007895D1 (de) 2007-09-13
WO2004078175A3 (fr) 2004-12-09
ES2290678T3 (es) 2008-02-16
EP1601355B1 (fr) 2007-08-01
PT1601355E (pt) 2007-11-15
AU2004216823A1 (en) 2004-09-16
ITFI20030058A1 (it) 2004-09-07
CA2518199A1 (fr) 2004-09-16
AU2004216823B2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
JP2006519799A (ja) Ｉｐ−１０が媒介した疾患の処置又は予防用の、チアゾリジンジオンを有する薬学的調製物
JP7313405B2 (ja) 線維症の治療
JP2020521734A (ja) 老化細胞除去化合物
Kang et al. Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trial
CA2998509A1 (fr) Polytherapie faisant appel au cenicriviroc pour le traitement de la fibrose
JP2003535034A (ja) ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
KR100917082B1 (ko) 면역염증 질환의 치료를 위한 조합
RU2012110592A (ru) Соединения и способ снижения мочевой кислоты
Morris et al. Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice
AU2020201980A1 (en) Combination of FXR agonists
Nie et al. S-allyl-l-cysteine attenuates bleomycin-induced pulmonary fibrosis and inflammation via AKT/NF-κB signaling pathway in mice
CA3100792A1 (fr) Procedes et compositions pour le traitement de la maladie d'alzheimer
US20070259913A1 (en) Prophylaxis of thromboembolic events in cancer patients
JP2005281235A (ja) 慢性拒絶反応抑制剤
KR20170012480A (ko) 당뇨병을 치료하기 위한 카페스톨
JP2002518448A (ja) 高血中コレステロールを治療する組成物および方法
WO2020200305A1 (fr) Utilisation d'une composition pharmaceutique contenant de l'hydroxyurée
EP2908820A1 (fr) Traitement de la fibrose pulmonaire à l'aide d'un inhibiteur de la cbp/caténine
EP3796901A2 (fr) Acides gras structurellement modifiés pour améliorer la régulation glycémique et traiter une maladie intestinale inflammatoire
TWI535443B (zh) 羽扇豆醇醋酸及薑黃素之協同組合用於治療或預防蝕骨細胞前驅物活化相關疾病
JP2006504769A (ja) 病理学的プロセスに関する遺伝子発現を制御するためのキナゾリノン組成物
Valtola Clinical insights into the pharmacokinetic aspects of fentanyl, metoprolol and oxycodone dosing after cardiac surgery
Bucci et al. Thromboangiitis Obliterans
KR20210065950A (ko) Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물
CN113301902A (zh) 非酒精性脂肪肝病患者的纤维化的治疗和抑制

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070221

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100927

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110203